Citalopram Tablet
Product Images NDC 71610-412

Table 1 shows the drug-placebo difference in terms of the number of cases of suicidality per 1000 patients treated. The data is organized by age range, and for patients under 18 years, there were an additional 14 cases compared to the placebo. For patients over 18 years, there were fewer cases of suicidality with the drug compared to the placebo, with a reduction of 564 and 265 cases per 1000 patients treated, respectively.*

The table shows the percentage of patients who reported treatment-emergent adverse events in placebo-controlled clinical trials for Citalopram compared to placebo. The adverse events are categorized based on body system and include autonomic nervous system disorders, central and peripheral nervous system disorders, gastrointestinal disorders, general disorders, musculoskeletal system disorders, psychiatric disorders, respiratory system disorders, and urogenital disorders. Only events reported by at least 2% of patients treated with citalopram are included, except for a few events with higher incidence in placebo. The denominator used for some adverse events was different for males and females.*

This is a table presenting the percentage of patients who discontinued treatment in short-term, depression trials due to adverse events associated with discontinuation. The table shows the adverse events associated with the discontinuation of treatment for patients who received either Citalopram or Placebo. The table indicates that a certain percentage of patients discontinued treatment due to adverse events such as asthenia, nausea, dry mouth, vomiting, dizziness, insomnia, somnolence, and agitation.*